Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 3 Impact of [18F]flutemetamol PET on patient management according to clinical diagnosis prior to PET

From: Diagnostic impact of [18F]flutemetamol PET in early-onset dementia

Pre-PET etiology

AD

(n = 145)

FTD

(n = 28)

OD

(n = 19)

NN

(n = 20)

PET result

Positive

Negative

Positive

Negative

Positive

Negative

Positive

Negative

n

111

34

6

22

8

11

9

11

AD medication

39 (35%)a

1 (3%)

3 (50%)a

0 (0%)

1 (13%)

0 (0%)

6 (67%)a

1 (9%)

Care

12 (11%)

1 (3%)

1 (17%)

1 (5%)

0 (0%)

0 (0%)

4 (44%)

3 (27%)

Ancillary investigations

0 (0%)

13 (38%)b

1 (17%)

3 (14%)

1 (13%)

2 (18%)

0 (0%)

2 (18%)

  1. Data are presented as n (%). Differences between impact of positive and negative PET results were assessed using χ2 tests
  2. aPositive PET > negative PET, P < 0.05
  3. bNegative PET > positive PET, P < 0.05
  4. PET positron emission tomography, AD Alzheimer’s disease dementia, FTD frontotemporal dementia, OD other dementia diagnosis, NN non-neurodegenerative diagnosis
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193